Skip to main content
. 2022 Nov 14;12:1042766. doi: 10.3389/fonc.2022.1042766

Table 3.

Association between clinicopathologic characteristics and mean expression (% positive expression) of GAGs and collagen types (t test and ANOVA, P<0.05).

Characteristics HS CS Col I Col III Col IV Col V
Age (years)
≤65 1.52 ± 0.16 12.21 ± 1.06 2.85 ± 0.21 23.67 ± 1.00 3.64 ± 0.35* 13.63 ± 0.87
> 65 1.58 ± 0.15 11.59 ± 1.09 2.75 ± 0.28 26.60 ± 1.13 5.03 ± 0.58 15.32 ± 1.02
Gender
Male 1.59 ± 0.16 10.95 ± 0.97 3.09 ± 0.23 25.52 ± 1.01 5.12 ± 0.53 13.94 ± 0.93
Female 1.50 ± 0.16 13.10 ± 1.18 2.47 ± 0.23 24.45 ± 1.16 3.29 ± 0.34** 15.01 ± 0.96
Tobacco History
Smoker/Former-smoker 1.63 ± 0.16 10.71 ± 0.93 2.91 ± 0.21 26.69 ± 0.99 3.82 ± 0.40 15.15 ± 0.93
Non-smoker 1.24 ± 0.22 14.52 ± 2.10 2.94 ± 0.46 25.78 ± 2.15 4.20 ± 0.66 15.79 ± 1.87
Histotypes
ADC 1.52 ± 0.15 13.31 ± 0.98 2.72 ± 0.20 25.58 ± 1.03 4.41 ± 0.43 14.17 ± 0.82
SqCC 1.55 ± 0.18 10.20 ± 1.23 3.01 ± 0.30 23.80 ± 1.20 4.14 ± 0.60 14.63 ± 1.26
LCC 1.86 ± 0.43 7.18 ± 2.62 2.57 ± 0.82 26.50 ± 2.97 4.07 ± 1.43 15.85 ± 2.86
T stage
T1 1.19 ± 0.16 13.98 ± 1.67 2.46 ± 0.34 24.47 ± 1.56 3.72 ± 0.52 15.50 ± 1.41
T2 1.76 ± 0.17 11.74 ± 1.07 2.99 ± 0.25 26.15 ± 1.13 4.92 ± 0.54 13.00 ± 0.82
T3 1.23 ± 0.20 9.67 ± 1.46 2.50 ± 0.31 23.44 ± 1.46 3.63 ± 0.68 16.61 ± 1.91
T4 2.43 ± 0.69 12.05 ± 2.55 3.91 ± 0.28 22.83 ± 2.55 3.44 ± 0.74 14.98 ± 1.54
N stage
N0 1.49 ± 0.13 12.31 ± 0.97 2.78 ± 0.20 25.79 ± 0.93 4.41 ± 0.43 15.50 ± 0.88
N1 1.50 ± 0.28 10.69 ± 1.51 2.80 ± 0.37 23.10 ± 1.52 4.41 ± 0.75 13.40 ± 1.13
N2 1.91 ± 0.35 11.84 ± 1.97 2.95 ± 0.46 24.30 ± 2.33 3.59 ± 0.75 10.85 ± 1.34*#
Pathologic stage
I 1.35 ± 1.16 14.30 ± 1.38 2.83 ± 0.34 26.90 ± 1.45 4.31 ± 0.67 14.84 ± 1.27
II 1.53 ± 0.16 10.34 ± 1.08&## 2.60 ± 0.22 24.68 ± 1.12 4.63 ± 0.48 14.93 ± 0.98
IIIA 1.95 ± 032 11.47 ± 1.57 3.38 ± 0.32 23.00 ± 1.38 3.66 ± 0.59 12.65 ± 1.30
Tumor size
≤3 cm 1.56 ± 0.19 13.72 ± 1.27 2.67 ± 0.25 25.43 ± 1.17 3.84 ± 0.42 14.51 ± 0.97
>3 cm 1.57 ± 0.14 10.65 ± 0.92* 2.90 ± 0.23 24.90 ± 1.03 4.64 ± 0.50 14.48 ± 0.93
Relapse
No 1.60 ± 0.16 11.71 ± 0.95 3.02 ± 0.23 25.57 ± 1.05 4.21 ± 0.47 15.10 ± 0.98
Yes 1.55 ± 0.20 13.19 ± 1.75 2.50 ± 0.29 23.38 ± 1.47 4.40 ± 0.59 14.24 ± 1.19
Adjuvant treatment
Chemotherapy
No 1.56 ± 0.15 12.56 ± 1.10 2.69 ± 0.24 25.58 ± 1.06 4.75 ± 0.50 15.68 ± 0.89
Yes 1.51 ± 0.17 11.03 ± 1.07 2.94 ± 0.24 24.48 ± 1.16 3.57 ± 0.41& 12.71 ± 1.04*
Radiotherapy
No 1.52 ± 0.14 12.00 ± 0.93 2.95 ± 0.20 24.89 ± 0.93 4.40 ± 0.41 14.78 ± 0.88
Yes 1.58 ± 0.19 11.70 ± 1.43 2.38 ± 0.28 25.72 ± 1.47 3.86 ± 0.57 13.50 ± 0.93

*P>0.05; **P>0.01; #N0 vs. N2, P=0.05; &P=0.07; ##Stage I vs. Stage II P=0.06

HS, heparan sulfate; CS, chondroitin sulfate; Col I, collagen type I; Col III, collagen type III, Col IV, collagen type IV; Col V, collagen type V; ADC, lung adenocarcinoma; SqCC: lung squamous cell carcinoma; LCC, large cell carcinoma.

Bolded values refer to a P-value with statistical significance (P<0.05).